Osteoporosis is a common disease characterized by porous bone structure, lower bone mass, and reduced bone strength. Osteoporosis is a condition where the regrowth of bone is slower than the breakage of a bone. It is estimated that worldwide, around 200 million people are affected by osteoporosis, which causes around 9 million fractures annually, which is a major public concern as the estimated cost of osteoporosis is about $19 billion in the United States alone. Women are more susceptible to osteoporosis than men due to their thinner bones, according to the International Osteoporosis Foundation.
Estrogen helps maintain bone structure; therefore, women at their menopausal stage are mostly get affected by osteoporosis. Geriatric populations are more likely to develop osteoporosis due to loss of bone minerals. Some of the risk factors for developing osteoporosis include an insufficient diet, a physically inactive lifestyle, smoking, drinking alcohol, a previous family history, and long-term use of steroids.
Rising geriatric and postmenopausal women, increasing prevalence of osteoporosis in younger populations, increased risk of hip, forearm, and spine fractures, and increasing R&D expenditures for new and innovative drug formulations are critical driving forces in the osteoporosis drugs market, while side-effects and adverse reactions of osteoporotic drugs, issues in regulatory approval for drugs, and lower public awareness restrain the market growth.
North America is expected to hold the major share of the osteoporosis drugs market, followed by the European market, due to its well-organized healthcare infrastructure, healthcare expenditure for R&D, and rising health awareness among the public. Asia-Pacific is anticipated to show higher growth due to its large population and growing health awareness.
The global osteoporosis drugs market is divided into the following segments:
Global Osteoporosis Drugs Market Revenue (US$ Mn), 2015-2025, By Drug Class
Bisphosphonates
Selective Estrogen Receptor Modulators (SERMs)
Hormone Therapy
Denosumab (Bone Metabolism Regulator)
Parathyroid hormone (PTH)
Others
Global Osteoporosis Drugs Market Revenue (US$ Mn), 2015-2025, By Geography
North America
US
Canada
Europe
UK
Germany
Rest of Europe
Asia-Pacific
Japan
China
Rest of APAC
Latin America
Brazil
Mexico
Rest of LATAM
Middle East and Africa
GCC
South Africa
the remainder of MEA
Key players identified for the global osteoporosis drugs market include:
A few major players in the osteoporosis drugs market include Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Amgen, Inc., Novo Nordisk A/S, and Actavis Plc. Pfizer, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., and others
This report offers the following:
An overview of the global markets for osteoporosis drugs
Market trends assessment for the period 2015-2025, including historical data for 2015 and projections through 2025, as well as respective CAGRs from 2017 to 2025.
Qualitative assessment tools such as market drivers, challenges, and future prospects
Market competition examination tools such as market share analysis and fractal map evaluation
Focus on each level of market segmentation based on product approvals, launches, and current and anticipated market dynamics.
A general overview of the industry structure.
Company profiles highlighting key information about the major players operating in the osteoporosis drugs market,
Frequently Asked Questions:
The market for Osteoporosis Drugs Market is expected to reach USD XX Mn By 2025.
The Osteoporosis Drugs Market is expected to see significant CAGR growth over the coming years, at XX%.
The report is forecasted from 2015-2025.
The base year of this report is 2014.
Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Amgen, Inc., Novo Nordisk A/S, and Actavis Plc. Pfizer, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd are some of the major players in the global market.
